September 18, 2014
ARLINGTON, Va. — HDMA President and CEO John M. Gray released the following statement on the Regulatory Transparency, Patient Access and Effective Drug Enforcement Act of 2014 (S.2862), introduced today by Senators Orrin Hatch (R-Utah) and Sheldon Whitehouse (D-R.I.)
“We are pleased that the Senate, particularly Senators Hatch and Whitehouse, have recognized the importance of promoting collaborative and transparent efforts between pharmaceutical industry stakeholders and federal regulators in reducing prescription drug abuse and diversion. Like its companion legislation — the Ensuring Patient Access and Effective Drug Enforcement Act of 2014 (H.R. 4709), sponsored by Reps. Tom Marino (R-Pa.), Marsha Blackburn (R-Tenn.), Peter Welch (D-Vt.) and Judy Chu (D-Calif.) — the bill will allow companies registered with the Drug Enforcement Administration to submit corrective action plans to address DEA concerns, while clarifying the Controlled Substances Act to give industry stakeholders clear understanding of their responsibilities under the law.
“We are hopeful that this bicameral momentum will continue, especially now that the House of Representatives has passed H.R. 4709. HDMA and the nation’s primary pharmaceutical distributors pledge to work closely with both chambers to ensure passage of this legislation.”
HDA Supports Hatch-Whitehouse Bill Addressing Drug AbuseWebsite design and development by Americaneagle.com, inc
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.